FindTrial
Sign In

Safety of 0.01% topical atropine sulfate eye drops for children and adolescents with myopia: A retrospective, real-world study conducted in China

Safety of 0.01% topical atropine sulfate eye drops for children and adolescents with myopia: A retrospective, real-world study conducted in China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061272
Enrollment
Unknown
Registered
2022-06-18
Start date
2022-06-06
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myopia

Interventions

Group 1:
Group 2:

Sponsors

Shenyang SinQi Eye Hospital Co., Ltd
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 15 Years

Inclusion criteria

Inclusion criteria: 1. Children and adolescents aged 6 to 15 (including the critical value), regardless of gender; 2. The diopter of any eye is between -0.5D~-4.0D, and the main clinical diagnosis is myopia; 3. Purchase and use 0.01% atropine sulfate eye drops at Shenyang Xingqi Eye Hospital, and the time range for the last purchase is from May 1, 2022 to May 31, 2022.

Exclusion criteria

Exclusion criteria: 1. The patient or his guardian refuses to participate in the study/refuses to accept follow-up; 2. The drug has been stopped for one month or more at the time of follow-up.

Design outcomes

Primary

MeasureTime frame
Incidence of adverse reactions;—

Secondary

MeasureTime frame
Accommodation functions;Fundus;Intraocular pressure;Lens;Pupil diameter;Medication duration;Cause for drug withdrawal;Electrophysiology;Incidence of systemic adverse reactions;—

Countries

China

Contacts

Public ContactXiaowen Wei

Shenyang SinQi Eye Hospital Co., Ltd

780964048@qq.com+86 13322446418

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026